用达帕格利弗洛辛治疗伦瓦替尼布诱导的蛋白尿症的治疗方法
J Matías Calabretta1, M Laura Iglesias1, Agostina Paggetta1
1División Endocrinología, Instituto de Oncología Ángel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina.
Medicina
|February 5, 2026
概括
达帕格利弗洛辛是一种-葡萄糖共同载体2型抑制剂,在接受伦瓦提尼布治疗的甲状腺癌患者中有效控制了严重的蛋白尿. 这表明SGLT2抑制剂可能有助于控制这种常见的不良事件.
科学领域:
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学 是一个学科.
背景情况:
- 蛋白尿是治疗伦瓦丁尼布的甲状腺癌患者 (30%) 的常见不良事件,伦瓦丁尼布是一种氨酸激酶抑制剂,向VEGF受体.
- 伦瓦提尼布诱导的蛋白尿的管理具有挑战性,通常需要控制动脉高血压.
- 晚期发病的3级蛋白尿发生在一个患有晚期放射性耐火性甲状腺癌的患者身上,尽管血压得到了充分控制.
研究的目的:
- 描述使用达帕格利弗洛辛 (dapagliflozin) 诱导的伦瓦提尼布蛋白尿的成功管理.
- 评估-葡萄糖共同载体2型 (SGLT2) 抑制剂在管理这种不良事件中的潜在作用.
主要方法:
- 一个病例报告,一名甲状腺癌患者在接受伦瓦提尼布治疗期间出现了3级蛋白尿症.
- 用达帕格利弗洛辛10毫克/天用于蛋白尿管理.
- 蛋白尿水平的监测和延续林瓦提尼布治疗.
主要成果:
- 达帕格利弗洛辛治疗迅速将蛋白尿从3级降低到1级.
- 伦瓦替尼布在持续良好的蛋白尿控制下成功地重新启动.
- 患者耐受得很好达帕格利弗洛辛,这表明其潜在的效用.
结论:
- 达帕格利弗洛辛是一种SGLT2抑制剂,在治疗严重的伦瓦提尼布诱导蛋白尿症方面表现出有效性.
- 在癌症患者中,SGLT2抑制剂可能代表伦瓦提尼布相关蛋白尿症的新疗法策略.
- 需要进一步的临床研究来证实SGLT2抑制剂在这种情况下的作用.
相关概念视频
01:26Tonsillitis II: Management
438
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
438
01:29Impression Management Techniques I: Managing Appearances
220
Appearance is a multidimensional aspect of self-presentation that encompasses observable attributes such as clothing, grooming, speech, and nonverbal behavior. These elements are often strategically managed to align with socially constructed expectations in different settings. For instance, individuals tailor their appearance during job interviews, social gatherings, or athletic events to meet the perceived norms of those environments.Contextual Adaptation and Social SignalsThe research...
220
01:19Managing Impressions
173
Impression management encompasses individuals' deliberate efforts to shape how others perceive them during social interactions. This behavior is often employed to conform to social norms, secure approval, or pursue specific goals. While it involves selective self-presentation, it is not necessarily deceptive; individuals frequently present authentic aspects of themselves that align with situational demands.Common strategies include:Ingratiation: where individuals use flattery or agreeableness...
173
01:19Management of Insomnia
657
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
657
01:24Cystic Fibrosis: Management
545
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
545
01:26Angina IV: Management
297
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
297